RxDoctor Payments Data

Megan Vissing, MD

Dermatology · New Albany, INNPI 1962856880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 402 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 24.1% of the total.

$7,128in general payments, 2019–2025

Across 402 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novartis$1K
  • Johnson & Johnson$787
  • Sanofi$482
  • Galderma Laboratories, L.p.$401
  • E.r. Squibb & Sons, L.L.C.$397
  • plus $2K from 18 others
$876,709in research payments, 2019–2025

Across 150 payments — averaging $5844.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acrotech Biopharma Inc.$211K
  • Takeda Pharmaceuticals U.S.A., Inc.$211K
  • Incyte Corporation$141K
  • Amgen$113K
  • E.r. Squibb & Sons, L.L.C.$72K
  • Arcutis Biotherapeutics, Inc.$37K
  • plus $92K from 6 others

What the payments were for

  • Food & beverage$6,86396%
  • Education$2654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,128 in reported general payments places this provider in the 65th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$192,985
Medicare patients
838
Services billed
3,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab24$92,930
Fluorouracil69$5,550
Calcipotriene26$3,320
Clobetasol Propionate117$2,566
Tacrolimus22$2,193
Metronidazole36$1,799
Ketoconazole155$1,667
Doxycycline Monohydrate58$1,617
Doxycycline Hyclate23$1,092
Triamcinolone Acetonide123$1,068
Hydrocortisone114$650
Ciclopirox24$337
Spironolactone15$297
MethotrexateMethotrexate Sodium18$174
Terbinafine Hcl15$110

Paid to pharmacies, not to this prescriber.

Other dermatology in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →